The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > REGULATORY
REGULATORY
- MHLW Not Discussing Single-Dose Use of COVID-19 Vaccine: Minister
February 24, 2021
- Incyte’s Pemigatinib Clears PAFSC, March Approval Likely
February 24, 2021
- LDP COVID-19 Project Team to Compile Proposal on Single Vaccine Dose
February 24, 2021
- Orphan Status Granted to Novo’s Concizumab, Eisai’s E7090 and More
February 24, 2021
- LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
- Whether to Get COVID-19 Vaccines Up to Individuals to Decide: Govt
February 22, 2021
- First Possible Adverse Reactions from Pfizer Vaccine Reported in Japan
February 22, 2021
- Up to 1.17 Million Vaccine Doses to Be Shipped for HCPs in First Half of March
February 22, 2021
- Govt Plans Ticket Barcode Scan for New Vaccination Tracking System
February 18, 2021
- Japan Might Reconsider Vaccine Use for Kids under Age 16 If Data Obtained
February 18, 2021
- Celgene’s CAR-T Liso-Cel Now in Line for Possible March Approval in Japan
February 18, 2021
- Japan Launches COVID-19 Vaccination Program
February 18, 2021
- MHLW Hints It Might Take 1 Year for Kobayashi Kako to Resume Operations
February 17, 2021
- COVID-19 Vaccine Being Rolled Out for 40,000 Healthcare Workers in Japan
February 17, 2021
- Pregnant Women Not Urged to “Make Efforts” to Get COVID-19 Vaccines
February 16, 2021
- Chugai’s Blood-Based Genomic Profiling Test Now in Line for March OK
February 16, 2021
- PAFSC Minutes for Pfizer Vaccine Review Due Out around Feb. 26
February 16, 2021
- 17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
February 16, 2021
- PMDA Review Report: Pfizer Vaccine’s Efficacy for Variants Not Gauged in Clinical Trials, Continued Info Collection Needed
February 16, 2021
- Japan to Start COVID-19 Vaccination on Feb. 17: PM Suga
February 15, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…